Reading IDXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDXX free→Reading IDXX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces First Quarter Results,” issued by the Company on May 5, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES,…
Executive Vice President, Global Strategy and Commercial — Nimrata Hunt, PhD: Dr. Nimrata Hunt is leaving her role with significant severance benefits.
Director — Ms. M. Anne Szostak: Ms. Szostak is retiring from the Board of Directors after her tenure since 2012.
shall be deemed to be furnished, and not filed. Exhibit No. Description of Exhibit 99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately. Dr. Collins’s decision to resign was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies or practices. The Company and Board t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of Nonqualified Deferred Compensation Plan On December 6, 2024, the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), upon the recommendation of the Compensation and Talent Committee of the Board (the “Committee”), approved and adopted the IDEXX Deferred Compensation Plan (the “Plan”). The Plan constitutes an un…
Entry into a Material Definitive Agreement. Effective as of October 31, 2024, IDEXX Laboratories, Inc. and certain of its affiliates entered into: (i) an Amendment No. 9 (the “U.S. Amendment”) to the Agreement effective as of October 16, 2003 between IDEXX Operations, Inc. and Ortho-Clinical Diagnostics, Inc. (“Ortho”), as amended by Amendment Nos. 1 to 8 and the Letter Agreement dated July 28, 2023 (the “Original U.S. Supply Agreement” and as amended by the U.S. Amendment, the “U.S. Supply A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2023, James F. Polewaczyk, Executive Vice President and Chief Commercial Officer of IDEXX Laboratories, Inc. (the “Company”), notified the Company of his intent to retire after more than 17 years of dedicated leadership and service, effective April 1, 2024. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 193…
Regulation FD Disclosure IDEXX Laboratories, Inc. (NASDAQ: IDXX) (“IDEXX”) is furnishing this Current Report on Form 8-K to provide further information regarding its operations in Russia. Since March 2022, IDEXX has significantly scaled back its operations in Russia, including the suspension of sales of veterinary diagnostic equipment; promotional, marketing, and hiring activities; and new business development and related investments. IDEXX’s 2021 annual revenue in Russia represented less tha…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.